Doris Hansen, MD

Dr Hansen is actively involved in clinical research evaluating investigational cellular therapies for relapsed and/or refractory multiple myeloma. She serves as an investigator on phase 1 and 2 trials including studies of BMS-986453, a dual-targeting BCMAxGPRC5D chimeric antigen receptor (CAR) T-cell therapy, and GC012F, a CD19 and BCMA-targeted CAR T-cell therapy.

She practices at the Moffitt Cancer Center Magnolia Campus and provides care in English. Dr Hansen maintains a strong commitment to advancing novel immunotherapeutic approaches to improve patient outcomes in malignant hematologic conditions.